High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection

被引:324
作者
Nichols, WG
Corey, L
Gooley, T
Davis, C
Boeckh, M
机构
[1] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA
[2] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA
关键词
D O I
10.1086/338624
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The impact of cytomegalovirus (CMV) serostatus (seropositive [(+)]or seronegative [(-)]) of the donor (D) and recipient (R) on mortality after allogeneic non-T cell-depleted stem cell transplantation (SCT) in the era of preemptive therapy was assessed among 1750 patients by means of multivariable Cox regression models. In an analysis that included only pre-SCT variables, D+/R+ and D+/R- patients had the highest risk for mortality. After neutropenia or the occurrence of CMV disease was controlled for only D+/R- patients remained at a significantly higher risk for mortality. Mortality due to bacteremia or invasive fungal infection was higher among D+/R- (18.3%) than D-/R- (9.7%) patients (P < .001). Thus, CMV serostatus remains associated with mortality; neutropenia due to ganciclovir administration and CMV disease explain the association with mortality among seropositive recipients. However, in D+/R- subjects, mortality appears to be associated with bacterial and fungal infection, indicating a possible immunomodulatory effect of primary CMV infection that was undetected despite intensive monitoring.
引用
收藏
页码:273 / 282
页数:10
相关论文
共 58 条
[1]   Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [J].
Boeckh, M ;
Bowden, RA ;
Gooley, T ;
Myerson, D ;
Corey, L .
BLOOD, 1999, 93 (05) :1781-1782
[2]   Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[3]   A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].
BOWDEN, RA ;
SLICHTER, SJ ;
SAYERS, M ;
WEISDORF, D ;
CAYS, M ;
SCHOCH, G ;
BANAJI, M ;
HAAKE, R ;
WELK, K ;
FISHER, L ;
MCCULLOUGH, J ;
MILLER, W .
BLOOD, 1995, 86 (09) :3598-3603
[4]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[5]   Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis [J].
Cenci, E ;
Mencacci, A ;
d'Ostiani, CF ;
Del Sero, G ;
Mosci, P ;
Montagnoli, C ;
Bacci, A ;
Romani, L .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06) :1750-1760
[6]   Th1 and Th2 cytokines in mice with invasive aspergillosis [J].
Cenci, E ;
Perito, S ;
Enssle, KH ;
Mosci, P ;
Latge, JP ;
Romani, L ;
Bistoni, F .
INFECTION AND IMMUNITY, 1997, 65 (02) :564-570
[7]   MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - A RANDOMIZED STUDY COMPARING CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION WITH BUSULFAN AND CYCLOPHOSPHAMIDE [J].
CLIFT, RA ;
BUCKNER, CD ;
THOMAS, ED ;
BENSINGER, WI ;
BOWDEN, R ;
BRYANT, E ;
DEEG, HJ ;
DONEY, KC ;
FISHER, LD ;
HANSEN, JA ;
MARTIN, P ;
MCDONALD, GB ;
SANDERS, JE ;
SCHOCH, G ;
SINGER, J ;
STORB, R ;
SULLIVAN, KM ;
WITHERSPOON, RP ;
APPELBAUM, FR .
BLOOD, 1994, 84 (06) :2036-2043
[8]   Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis [J].
Craddock, C ;
Szydlo, RM ;
Dazzi, F ;
Olavarria, E ;
Cwynarski, K ;
Yong, A ;
Brookes, P ;
de la Fuente, J ;
Kanfer, E ;
Apperley, JF ;
Goldman, JM .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) :228-236
[9]   Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial [J].
Deeg, HJ ;
Lin, DY ;
Leisenring, W ;
Boeckh, M ;
Anasetti, C ;
Appelbaum, FR ;
Chauncey, TR ;
Doney, K ;
Flowers, M ;
Martin, P ;
Nash, R ;
Schoch, G ;
Sullivan, KM ;
Witherspoon, RP ;
Storb, R .
BLOOD, 1997, 89 (10) :3880-3887
[10]  
DEGAST GC, 1992, BONE MARROW TRANSPL, V9, P221